Cereno Scientific announces changes in the executive management team strengthening skill set and capabilities in preparation for expanded clinical portfolio
Cereno Scientific (XSAT: CRNO B) today announced changes to the company’s executive management team with the expansion of Dr. Björn Dahlöf’s role and the appointment of a Head of IR & Communications. Dr. Björn Dahlöf has been the company’s Chief Medical Officer (CMO) since 2018 and is now also stepping into the roles Chief Scientific Officer (CSO) and Head of Clinical Development. Josefine Göranson will join as the Head of IR & Communications. These changes will strengthen the skill set of the executive management team and heighten readiness to support the upcoming expansion of the clinical portfolio.
“We have a highly promising drug portfolio with CS1 in Phase II and two preclinical programs CS014 and CS585, both in preparation for clinical development. I strongly believe that we are on the cusp of a new era with a more mature Cereno with an experienced leadership team with the right skill set to support the company and our ambition. I am pleased to have Björn now spearheading our research and clinical development and I am happy to welcome Josefine to level up our IR & communications activities,” said Sten R. Sörensen, CEO of Cereno Scientific.
Dr. Björn Dahlöf, has been a board member since the company was started in 2012 and the Chief Medical Officer (CMO) since 2018. He will now also take on the roles Chief Scientific Officer (CSO) and Head of Clinical Development effective immediately. Dahlöf has practiced General Internal Medicine at Sahlgrenska Hospital for over 35 years and is an Associate Professor of Cardiovascular Prevention at the Sahlgrenska Academy, University of Gothenburg. Dahlöf has extensive experience in cardiovascular research, pharmacology, drug development, and all phases of clinical trials. He has lectured in these areas internationally and, is an author of more than 400 scientific publications. He also has lengthy experience as an adviser to pharmaceutical companies on drug development in all phases from preclinical development to larger lifecycle management studies after registration. Dahlöf has initiated and led several major national and multinational mortality and morbidity studies that have had significance for guidelines in cardiovascular prevention.
Josefine Göranson will step into the newly formed position Head of IR & Communications as of December 15, 2022. Göranson has most recently been a Communications Lead at the Swedish furniture store IKEA. Prior to this, she gained extensive experience in the life science sector having held a variety of Communications & Marketing roles with increasing responsibilities at the global med-tech company Atos Medical during 15 years at the company. Göranson will be part of the executive management team at Cereno.
Niklas Bergh, co-founder of Cereno and former Chief Scientific Officer (CSO), will remain as a deputy board member and senior advisor to the company. He will continue to be an advisor across Cereno’s preclinical and clinical development programs. Bergh is an Associate Professor in Experimental Cardiology at Sahlgrenska Academy, University of Gothenburg, and works as a cardiology consultant at Sahlgrenska University Hospital in Gothenburg, Sweden, and has the responsibility of treating patients with cardiovascular disease including those affected by thrombosis e.g., myocardial infarction, heart failure, and heart transplantation, as well as pulmonary arterial hypertension (PAH).
For further information, please contact:
Hans Naess, interim CFO
Phone: +46 793 40 79 00
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.